University of California, San Francisco | UCSF Memory and Aging Center
Status and phase
Conditions
Treatments
About
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
Full description
This study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Open-label Extension Entry Criteria
Key Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
64 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal